Shibeikang announced the completion of Series B financing, with listed company CHENGDA PHARMA as the exclusive strategic investor

Recently, Chengdu Shibeikang Biopharmaceutical Technology Co., Ltd. announced the completion of its Series B financing. This round of financing was exclusively strategically invested by the listed company CHENGDA PHARMA. The funds raised will mainly be used to accelerate the construction of the R&D pipeline, expand the R&D laboratory, and promote the international application process of core products. According to Shibeikang, it previously received investments from industrial investors such as Fosun Pharma and Chuan Chuang Investment, as well as local investment institutions during its early startup phase